Antibody Platforms

Antibodies have become a backbone approach of modern cancer medicine. Our platforms aim to expand their application to broader patient populations and novel indications.

Next-generation Checkpoint Immunomodulators

Multi-specific antibodies that can simultaneously bind different targets on cancer and immune cells are a powerful new therapeutic option for the treatment of solid tumors. With our Next-generation Checkpoint Immunomodulators platform, we can create novel bispecific antibodies that are designed to activate immune cells via two simultaneous routes: 

  1. one arm of the antibody binds and thereby blocks target structures (such as CD40 or PD-L1) on the surface of immune cells that are used by cancer cells to silence the immune cells, and 
  2. the other arm binds to an activating receptor (such as 4-1BB) on the surface of immune cells, triggering stimulation of their functions.

By blocking the “off-switch” on immune cells that cancer cells use to silence the immune system and simultaneously activating immune cell functions, we aim to circumvent or even reverse the immune evasion induced by tumor cells, a key tactic particularly for fighting advanced-stage and resistant cancers.

At a glance: Our Next-generation Checkpoint Immunomodulators Platform

Concept: Bispecific antibodies enhancing immune cell function to promote an anti-cancer immune response

Mechanism: Upon simultaneous binding, our bispecific antibodies stimulate immune cell function (via binding to 4-1BB) and block inhibitory signals (via binding to CD40 or PD-L1)

Development Approach: 50:50 cost share with Genmab

Therapeutic Areas: Solid tumors, including non-small cell lung cancer

 

At a glance: Our Next-generation Checkpoint Immunomodulators Platform

Concept: Bispecific antibodies enhancing immune cell function to promote an anti-cancer immune response

Mechanism: Upon simultaneous binding, our bispecific antibodies stimulate immune cell function (via binding to 4-1BB) and block inhibitory signals (via binding to CD40 or PD-L1)

Development Approach: 50:50 cost share with Genmab

Therapeutic Areas: Solid tumors, including non-small cell lung cancer

Targeted Cancer Antibody Discovery Engine 

Our Targeted Cancer Antibody platform uses sophisticated discovery engines to identify novel cancer antibodies with excellent specificity and binding affinity for unique tumor targets as well as reduced risk for unwanted immune reactions. The target structures on the tumor surface can either be proteins or tumor-associated carbohydrate antigens (TACAs), another promising target for the development of therapeutic antibodies. This proprietary antibody platform is also used for the identification of alternative antibody formats. With the use of the Antibody discovery platform, tumor- and immune cell specific binders are thus made available across our drug classes. 

At a glance: Our Targeted Cancer Antibody Discovery Engine 

Concept: Antibodies targeting novel, highly specific cancer antigens involved in tumor and metastasis formation

Mechanism: Monoclonal antibodies binding to cancer-specific antigens flagging tumor cells for destruction by immune cells

Development Approach: Worldwide rights, fully owned

Therapeutic Areas: Solid tumors, including pancreatic cancer

At a glance: Our Targeted Cancer Antibody Platform

Concept: Antibodies targeting novel, highly specific cancer antigens involved in tumor and metastasis formation

Mechanism: Monoclonal antibodies binding to cancer-specific antigens flagging tumor cells for destruction by immune cells

Development Approach: Worldwide rights, fully owned

Therapeutic Areas: Solid tumors, including pancreatic cancer

Read also